Close Menu

Bucking the Trend

This may mess up your "merger madness" bracket (kind of like Villanova is doing for the basketball brackets): Eli Lilly is not interested in a merger with Bristol-Myers Squibb, reports the Financial Times. CEO John Lechleiter told the FT that he'd rather "work to boost his company's internal development of experimental medicines alongside selective smaller-scale deals."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.